According to our results, IGU + MTX had a positive impact on efficacy and safety in patients with RA by both increasing ACR criteria values, namely ACR20, ACR50, and ACR70, and decreasing clinical indexes including DAS28, ESR, CRP, VAS (PGA), and VAS (PhGA). The gene discussed is CRP; the disease is rheumatoid arthritis.